🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
23.16
-0.43 (-1.82%)
At close: Nov 20, 2026, 4:00 PM EST
23.16
0.00 (0.00%)
After-hours: Nov 20, 2026, 7:30 PM EST
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 11, 2026

Summary

RAP-219’s epilepsy phase III trials are progressing, with ~$815M in cash funding trials through end-2029. Bipolar phase II results support plans for an FDA meeting early next year and two parallel phase III trials; an injectable readout is expected in Q3 next year.

Paul Matteis
Analyst, Stifel

All right. Thanks very much. Happy to be moderating this fireside chat with the Rapport Therapeutics team. With me is Abe Ceesay, CEO, and Troy Ignelzi, CFO. Maybe I'll just turn it over to Abe and Troy to give a quick update on the company, as it relates to the FOS and now also bipolar program. Maybe, Troy, you could also touch upon the recent financing and cash runway.

Abe Ceesay
CEO, Rapport Therapeutics

Great. Paul, thank you so much for the opportunity and the time today. Yes, Rapport Therapeutics, just a quick reminder, a company that is focused on precision neuroscience, leveraging receptor-associated protein science. Our lead program is a TARPγ8 AMPA modulator program. We have always viewed this program as a pipeline in a product opportunity, and that's the strategy that we took from the outset of launching the company. We realized the first step of that pipeline in a product opportunity last year with the release of our phase II data, proof of concept data in focal onset seizures, that really had unprecedented results, one that we think is going to be a very meaningful product for patients in the future. The second indication that we pursued was in bipolar mania.

Bipolar mania, just by its inherent characteristics, is a lower probability of success indication from epilepsy, given the lack of preclinical to clinical translation, but one based on our understanding of the biology and mechanistic rationale, we believed in. We've taken the next step with achieving proof of concept in bipolar mania, just about over a little over a month ago. So where we stand today is we see a program that has two shots on goal, high probability of success in terms of translation into phase III, with a multi-billion dollar opportunity across each indication individually.

Troy Ignelzi
CFO, Rapport Therapeutics

Yeah, and now, to Paul's question, with that data, we leveraged into a financing that was completed a little over a week ago that has now taken our cash to right around $815 million, which takes us through the end of 2029. Importantly, that gives us an opportunity to complete four phase III proof of concept trials. We'll also have a fifth ongoing with a primary generalized tonic-clonic seizure, which is the second largest of the epilepsy populations. Then we've got some other meaningful milestones coming out, in particular, so a readout of open-label extension data from our phase II that we'll talk about, but also our long-acting injectable program readout in the third quarter of next year. So all of those events are funded.

Paul Matteis
Analyst, Stifel

Okay, great. Maybe we will jump around and go in the order of proximity of catalysts. This open-label data that is coming out, maybe just set the stage for people in terms of what we should expect in terms of the disclosure, and for you guys, what would be a reaffirming outcome?

Abe Ceesay
CEO, Rapport Therapeutics

Sure. As in all open-label extension studies, really the primary goal is safety. We believe that this data is going to be a meaningful safety update for the program in epilepsy. It is important to understand the dynamics of this open-label extension study for RAP-219. This was not the traditional open-label extension study where patients went directly from treatment into an open-label extension study. As a reminder, our phase II study had eight weeks of treatment, eight weeks of washout. Patients were washed out of their drug for eight weeks, and then there was actually a gap between that period and when they rolled into an open-label extension. The reason I say that is that the patient's baseline is going to be completely different from when they enrolled in the treatment period of the phase II study.

With that said, we still have re-baselined the patients. We believe that the relative exposures that we are going to be able to report on in the December update will be in the three to six month range, and we will be collecting efficacy data as well. That efficacy data will be defined by both the long episode or electrographic seizure data, but also clinical seizures as well.

Paul Matteis
Analyst, Stifel

Okay. At this point, on the safety side, if something had emerged that changed your perception of the profile, you would know, right?

Abe Ceesay
CEO, Rapport Therapeutics

Yeah, we would. We would know. We monitor all of our trials in a consistent manner for emerging safety or any other issues that one might be looking at as you conduct clinical trials. We believe that this is going to be a really meaningful update as we just think about the overall safety profile for RAP-219.

Paul Matteis
Analyst, Stifel

Yep. Okay. As it relates to the epilepsy phase III program, maybe talk a little about how that's going in terms of enrollment and execution. I know timelines here are a big focus because of the wide range of analog trials. What's the current thinking there?

Abe Ceesay
CEO, Rapport Therapeutics

Yes. We're pleased with the ongoing progress of the phase III program. We have two phase III studies, FOCUS-1 and FOCUS-2. Both have roughly about 320 patients that are looked to be enrolled in each study. As you know, Paul, all of the FOS phase III programs are global in nature. To your point, they do take a while to enroll, just based on kind of the stringent approach one takes to really screening, baseline characteristics, et cetera. For us, we believe there's a few reasons why we can execute these trials in a quality manner as well as do it efficiently. The first and foremost is quality.

We believe we have brought kind of the best thinking forward, partnering with groups such as the Epilepsy Study Consortium to really understand that patients are screened appropriately, patients are trained the right way in terms of how they count seizures. From a timing perspective, we've done a couple things. One is we partnered with a company in China to open up China as a country to enroll. Historically, China has not been accessed in phase III programs. Company is a company by the name of Tenacia, which is 100% neuroscience focused in China. The other aspect is really the qualities of the asset as well are super important as you think about enrollment. As it relates to RAP-219, this is a drug that doesn't have drug-drug interactions.

We're not competing with any other mechanisms outside of any overlapping AMPA modulators, but that's not a really big issue for us as we think about enrollment. The whole point here is the top of the funnel is much wider than other programs. We're not guiding on delivery of data yet, but we think probably middle of next year we'll be in a position to guide.

Paul Matteis
Analyst, Stifel

Okay. That's great. I mean, the phase I-B data is, I mean, it's unquestionable, the effect size and the corroboration with the long episodes. I think the only question we think about when we sort of extrapolate to the phase III is, how similar is that phase III population? Is it more heterogeneous? Could that cause some efficacy? What's your perspective overall there?

Abe Ceesay
CEO, Rapport Therapeutics

Yeah. I think there's no doubt that the population in phase III will be more heterogeneous. I mean, that's just the nature of going to a broader population. But the heterogeneity, I think, is more defined by the fact that this patient population will not have, or the majority of patients will not have, it'll be probably, if any, a small number of patients would have the RNS device.

Paul Matteis
Analyst, Stifel

Right.

Abe Ceesay
CEO, Rapport Therapeutics

You don't have the corroboration in a phase III trial of the electrographic seizure or long episode biomarker. But one of the things that we look at in the phase II data is a few things. One is this patient was a highly refractory patient in our phase II study. The majority of patients were on three or four to five medications, including, and I'm including the RNS device in that. Their baseline seizure count was around 10, which is very similar to phase III trials. And when you look at the overall profile of these patients, if anything, we think the phase III patient population won't be as refractory. So we think that there's a really high likelihood that the results that we saw in phase II will translate very well into phase III.

Paul Matteis
Analyst, Stifel

Yep. Okay, great. On the safety side, do you want to just, at this point now, talk about the totality of the data you have, not just in epilepsy, but also in bipolar disorder?

Abe Ceesay
CEO, Rapport Therapeutics

Sure. So we have roughly 250 subjects now that have been exposed to RAP-219. That is across all of our programs, both epilepsy, as you said, Paul, as well as bipolar. We believe, and we have always felt that we have a really good understanding of the safety of RAP-219, the tolerability profile of RAP-219 as well. The drug, one, is consistent with the target biology. So by avoiding hindbrain structures, we're not seeing the most bothersome and burdensome AEs that are associated with anti-seizure medications, but also associated with atypical antipsychotics as you think about bipolar mania. So we're not seeing sedation, we're not seeing somnolence. We're also not seeing any of the AEs that are associated with the dopaminergic pathways, such as metabolic changes, akathisia, extrapyramidal symptoms. So that's very compelling and differentiating.

In terms of what people think about, given the somewhat similar approach in terms of AMPA modulation, we're doing it very differently by targeting a receptor-associated protein. But what's in people's minds is the Fycompa experience, and will this drug induce any behavioral type of AEs? What we've been really encouraged by is we have not seen those types of behavioral AEs, and those behavioral AEs are hostility as well as homicidal ideation, which are very different from, say, agitation or anxiety.

Paul Matteis
Analyst, Stifel

Right.

Abe Ceesay
CEO, Rapport Therapeutics

Importantly, when you look at our bipolar data, the most improvement that we saw in the drug was actually on those domains, was on hostility as well as irritability. Patients improved on treatment as compared to placebo in a significant manner.

Paul Matteis
Analyst, Stifel

Yep. Okay. Makes sense. Certainly the bipolar data, I think, is helping assuage that risk there. Do we understand, like, are you guys Has anyone furthered the understanding of Fycompa and why it has that problem? The whole regional selectivity thesis on RAP-219 we always found super appealing, but then it's always hard in neurology to really point to a brain area and say, this is causing that.

Abe Ceesay
CEO, Rapport Therapeutics

It is. Outside of we know what is really driven by engagement in the hindbrain, because you see that across the board for anti-seizure medications. If you're interacting with receptors in the hindbrain that are causing kind of sedation, somnolence, as well as gait impairment. The behavioral aspect, it's really not well understood, but what's really important here is, if you look at the rates of these behavioral rage type of AEs with Fycompa, it's extremely low. We're talking about like 2%. Sometimes if you look at the data, it could be 1%. The drug that is the most widely used anti-seizure medication has the highest rates of aggression.

Paul Matteis
Analyst, Stifel

Levetiracetam?

Abe Ceesay
CEO, Rapport Therapeutics

Levetiracetam.

Paul Matteis
Analyst, Stifel

Yeah.

Abe Ceesay
CEO, Rapport Therapeutics

It has the highest rates of aggression as well as what is called Keppra rage.

Paul Matteis
Analyst, Stifel

Maybe help people understand then, why Fycompa is a commercial flop, if not that.

Abe Ceesay
CEO, Rapport Therapeutics

Yeah. Actually, the commercial viability of Fycompa has not really been impacted by this concern of behavioral AEs. The dose-limiting toxicity for Fycompa is really sedation as well as gait impairment. Patients cannot tolerate effective doses. They are completely snowed by the drug, it puts them to sleep, and they have significant gait impairment. That has been the issue and the reason why clinicians as well as patients can't tolerate it, and that's the reason why clinicians have not used the drug. If you were to talk to clinicians, they would tell you that they never have seen the rage associated with Fycompa.

Paul Matteis
Analyst, Stifel

Hmm. Interesting. Okay. On the bipolar side, again, I thought the psych AE data, the sub-component domain, all of that was super encouraging. I think the one data point some investors fixated on was dropout rates and difference between drug and placebo, and how to make sense of that being discordant from the AE data. What would you say to that?

Abe Ceesay
CEO, Rapport Therapeutics

Sure. There was an imbalance in discontinuations between the treatment group as well as the placebo group. Interesting, when you look at the overall discontinuation rate in kind of that low 20-ish percent, that is really consistent with all other previous trials. The real difference here was that the placebo rate was a bit lower, I think in roughly the 11-ish percent range was lower than historic trials. The main reason for discontinuation was withdrawal of consent. It was not AEs. The discontinuation rate to AEs was pretty low, and low compared to other trials. Withdrawal of consent is an interesting one. It was to family reasons or patients ultimately just wanted to leave the unit, and this is an inpatient study, and ultimately were no longer a part of the study. We have analyzed that data, and we think we have a good understanding of the data.

On a high level, what we saw in the placebo group is those patients that discontinued were either at where they were at baseline or worsening, and the patients in the treatment group were either at baseline or actually improving. One dynamic that often occurs in these studies is that when patients are feeling better, they want to get out of an inpatient unit. So that's one thing that we're going to consider as we think about the phase III design. But that imbalance, what we're really confident in is that imbalance is not driven by a higher rate of AEs.

Paul Matteis
Analyst, Stifel

Yep. Okay. On the efficacy side, you guys were targeting this 4-point difference, you were just short of that. Why did you say, you know what? We still think this is strong enough data. We should be advancing it. We should be investing in future studies. What led you to sort of overcome that?

Abe Ceesay
CEO, Rapport Therapeutics

Yeah. I think the first is the totality of the data. So, RAP-219 achieved statistical significance across both the primary as well as the secondary endpoint, and also had significant effects on those individual domains of the YMRS that importantly are the most important domains of the YMRS. They're the reason why, one, patients are hospitalized, and it's the reason why patients can't get out of the hospital if they're irritable as well as hostile, and we saw the most improvement there. The second is, it's important to look at the history of bipolar development. I think one of the best case studies is looking at a drug like Abilify, which is the highest revenue drug of all time in bipolar.

If you look at their experience in bipolar mania trials, they had a least square mean difference in the 2s all the way up to the 5s. So, there is some variability that occurs, and one of the things that we also looked at was the actual trial itself, and our belief is this is a novel MOA. Trying to bring a novel MOA into a neuropsych indication is a difficult thing to do, but we achieved what we wanted to achieve in terms of statistical significance, and whether it be dose as well as optimizing the protocol, we believe that there's a good chance that we can improve the outcome as we think about phase III trials.

Paul Matteis
Analyst, Stifel

Yeah, that was my next question. What can you do differently in the next study?

Abe Ceesay
CEO, Rapport Therapeutics

Yeah. The first and probably most meaningful thing we can do is dose. We believe we can increase the dose. We took in a dose of 0.75. We were confident that that was going to be a therapeutic dose, and it was a therapeutic dose and an efficacious dose. As you know, we have also assessed the 1.25 dose in our epilepsy trials, and we know that that dose is also highly effective and well-tolerated. By bringing in a 1.25 dose, what our modeling of our PK shows us is the same concentrations that we achieve with 0.75 at day 21, this is a three-week trial, we can actually pull in those concentrations and achieve those same concentrations at day seven or 10.

We think by pulling that in and having a higher dose, if you saw the deepening effect over time, that has an opportunity to really improve the impact that one may see with RAP-219. The second is, really comes down to thinking about placebo. The reality of this trial is the treatment effect that we saw with RAP-219, around 15.4, is as good or if greater than drugs that are seen in this class, atypical antipsychotics. The difference is we had a higher placebo rate. Many trials in the phase III setting are done in Eastern Europe as well as the U.S., which has really been able to balance the placebo impact, and we think that by doing that, we will be able to better control the placebo rates.

There are some other small things that we are looking at in the protocol, as one does going from phase II to phase III, but I think the trial where it is run and then bringing the 1.25 dose is one, going to allow us to maintain the effect that we saw in the phase II study, but at the end of the day, we really believe we might be able to enhance it.

Paul Matteis
Analyst, Stifel

Yep. Okay, great. Anything else to add on bipolar?

Abe Ceesay
CEO, Rapport Therapeutics

No.

Paul Matteis
Analyst, Stifel

I guess, what's the next step there?

Abe Ceesay
CEO, Rapport Therapeutics

The next step is to get in front of the FDA, and we expect to do that early next year at an end of phase II meeting. From that, look to initiate two parallel phase III trials. The two points that I would add here on bipolar is, let's not forget that we designed the phase II study to be a registrational trial and meet the level of confirmatory evidence, and we feel that these results really support that. So our strategy here is to, in kind of the old adage of neuropsych, run three trials to get two positive trials. The last thing I'll wrap up with bipolar is, this is a condition and an indication that has not had a novel MOA in over three decades.

The opportunity to bring a novel MOA to bipolar could be transformational, and that's kind of the feedback that we're hearing from the community on the results that we've produced thus far.

Paul Matteis
Analyst, Stifel

Yep. Okay, great. When will we get that regulatory update, you think?

Abe Ceesay
CEO, Rapport Therapeutics

We do not really guide on regulatory outcomes per se in terms of our interactions with the agency, but clearly if you have a successful end of phase II meeting, if you are starting the trial, that deems success.

Paul Matteis
Analyst, Stifel

Yep. Okay. As it relates to the LAI, how do you think about the commercial thesis there in epilepsy specifically? On the one hand, you can see all the value, but as it relates to compliance, I can totally see why physicians love it. On the other hand, the LAIs in psych have often become big after there is a lot of real-world experience with the oral. What is the thought on when and how you can make that a big product?

Abe Ceesay
CEO, Rapport Therapeutics

Yeah. The feedback that we have received is that an LAI for epilepsy would be transformational. It would be game-changing for the way clinicians think about introducing a novel ASM. The reason for that is if you were to talk to patients, their caregivers, clinicians, the scariest day for a patient living with epilepsy is when they forget their dose.

Paul Matteis
Analyst, Stifel

Right.

Abe Ceesay
CEO, Rapport Therapeutics

The risk of breakthrough seizures are real. The morbidity and unfortunately sometimes mortality associated with a breakthrough seizure is something that people are really concerned about. That is really the need. Can I have a therapy that patients tolerate, and then ultimately if I can have drug on board for a significant period of time, that alleviates some of that concern? Your commercial approach is not far off from the way that we think about it, except that with neuropsych, many of the LAI strategies are done much later in commercial adoption and primarily thinking about how do you extend the exclusivity period. That is part of our strategy, but we would look to introduce it much earlier. Call it anywhere from 18 to 36 months after launching the oral so physicians can really get comfortable with the oral therapy and then be able to introduce the LAI.

What we see in our market research is it has the opportunity to double sales with RAP-219 in epilepsy, and that's really driven by two things. One is, it has the ability to have premium pricing above and beyond the oral, and the second is what we see is it changes the share dynamics completely. It brings RAP-219 way up the treatment algorithm as early as second line because patients and physicians want access and they know they need to be able to step through the oral therapy to get to the LAI.

Paul Matteis
Analyst, Stifel

Okay. Makes sense. In the last couple minutes here, anything else you guys want to hit on or add?

Troy Ignelzi
CFO, Rapport Therapeutics

No, I don't think so.

Abe Ceesay
CEO, Rapport Therapeutics

Yeah.

Troy Ignelzi
CFO, Rapport Therapeutics

I think there was a lot of enthusiasm going into the bipolar results, a lot of skepticism, I think, about whether it would work or not. As Abe alluded to at the beginning, there are no animal models. I think the results that came out of that are gradually, the more people we talk to, the more people that are digging into it are appreciating a novel mechanism in this space, first time in 30 years with the profile that we've seen, is really something exciting to be pursued.

Paul Matteis
Analyst, Stifel

Yeah.

Troy Ignelzi
CFO, Rapport Therapeutics

We are hearing a lot of that.

Paul Matteis
Analyst, Stifel

Absolutely. Great. Well, congrats on the progress, guys. Appreciate you joining.

Abe Ceesay
CEO, Rapport Therapeutics

Thank you.

Troy Ignelzi
CFO, Rapport Therapeutics

Thanks, Paul.

Paul Matteis
Analyst, Stifel

Awesome.